Structure-based design of CYP51 inhibitors and their testing as antiprotozoan, antifungal and cholesterol-lowering agents

We have developed two compounds that are under NIH consideration to proceed to clinical trials as drug candidates for Chagas disease (American tripanosomiasis) and Leishmaniasis. Any help with product development plan participants will be greatly appreciated. 

Galina Lepesheva [Email]
Research Professor of Biochemistry
Location

Mendoza, Argentina; Minsk, Belarus; Rio de Janeiro, Brazil; Paris, France; Swansea, United Kingdom

Contacts

N/A

Program Type

Research

Funding Type

Grants

Region

Central and South America, Europe 

Global Health Topics

Basic Sciences, Infectious Diseases, General Medicine, Neglected Tropical Diseases

Eligibility

Post-doctoral students, residents, or trainees

Program Length

Flexible, depending on the individual's interests and needs

VU Affiliation

The program is affiliated with Vanderbilt.

Language(s)

The program does have a language requirement (English).